• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Duloxetine DR Teva
    / Teva

    Active Ingredient
    Duloxetine (as HCl) 20, 30, 60 mg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    30 X 30 mg

    partial basket chart 53931 4612


    30 X 60 mg

    partial basket chart 53932 4614

    Related information


    Adults: Swallow whole and should not be chewed or crushed, nor should the be opened and its contents sprinkled on food or mixed with liquids; can be given without regard to meals.
    Major Depressive Disorder: A total dose of 60 mg/day.
    Generalized Anxiety Disorder: starting dose is 60 mg x 1dly; may be desirable to start at 30 mg once daily for 1 week, to allow adjustm. before increasing to 60 mg once daily. Safety of doses above 120 mg once daily has not been adequately evaluated.
    Diabetic Peripheral Neuropathic Pain:  60 mg x 1 dly. For pts. for whom tolerability is a concern, a lower starting dose may be considered; give a lower starting dose and gradual increase in dose for patients with renal impairment.
    Fibromyalgia60 mg x 1 dly; begin at 30 mg once daily for 1 week, to allow patients to adjust to the medication before increasing to 60 mg once daily.
    Chronic Musculoskeletal Pain: 60 mg x 1 dly; dose may be started at 30 mg for one week, to allow patients adjust  to the medication before increasing to 60 mg once daily. There is no evidence that higher doses confer additional benefit.
    Pediatric Use: Safety and effectiveness in the pediatric population have not been established.                        


    Treatment of major depressive episodes.
    Management of neuropathic pain associated with diabetic peripheral neuropathy.
    Treatment of generalized anxiety disorder (GAD).
    Management of fibromyalgia.
    Management of chronic muscoskeletal pain when other therapies have failed or are contra-indicated.


    Hypersensitivity to the active substance or to any of the excipients.
    Liver disease resulting in hepatic impairment. Severe renal impairment.
    Patients taking other medicines containing duloxetine. Duloxetine DR Teva 30, 60 mg should not be concomitantly used in combination with monoamine oxidase inhibitors (MAOIs) or within 14 days after using MAOIs Initiation of treatment with MAOIs should be started only after 5 days’ elapse from stopping treatment with Duloxetine DR Teva 30, 60 mg.
    Duloxetine DR Teva 30, 60 mg must not be used in combination with fluvoxamine, thioridazine, cimetidine, quinolone antibiotics such as ciprofloxacin or enoxacin.
    Patients with uncontrolled narrow-angle glaucoma.

    Teva Pharmaceutical Industries Ltd, Israel